Follow-up of Sequential Chemotherapy and Stimulation for Fertility Preservation in Young Patients With Breast Cancer (KSF2)

Follow-up of Sequential Chemotherapy and Stimulation for Fertility Preservation in Young Patients With Breast Cancer

Long-term Follow-up of Sequential Chemotherapy and Stimulation for Fertility Preservation in Young Patients Treated for a Breast Cancer

Interventional research with low risks and constraints, prospective and monocentric on the assessment of long-term fertility in patients who underwent an adjuvant sequential chemotherapy with or without a controled ovarian hyperstimulation. This study follows a previous one called NCT 01614704.

The patients will have a follow-up once a year during ten years beginning at the end of their chemotherapy. They will have a consultation in oncology consisting of: a clinical exam, a collection and follow-up of oncological data a collection of ongoing cancer treatments and a consultation in gynecology consisting of: a pelvic ultrasound scan (for AFC: Antral Follicle Count) a biological test (FSH, LH, E2, AMH) a collection of gynecological data, contraception and reproductive medicine

Consultation in oncology: collection of oncological data and ongoing cancer treatments, clinical exam Consultation in gynecology: collection of gynecological data, contraception and reproductive medicine

for patients who underwent adjuvant sequential chemotherapy of anthracycline and taxane separately, depending on whether or not they have had Controlled Ovarian Hyperstimulation

describing the pregnancy type - number of pegnancies spontaneous versus assisted, with ot without the use of frozen gametes)

describing the pregnancy outcome : miscarriage or single or multiple birth separately, depending on whether or not they have had Controlled Ovarian Hyperstimulation

Assessment of the gonadotoxicity of the adjuvant sequential chemotherapy based on anthracyclines and taxanes - AMH rate

Assessment of the gonadotoxicity of the adjuvant sequential chemotherapy based on anthracyclines and taxanes - Antral Follicle Count

in terms of Antral Follicle Count depending on whether or not they have had Controlled Ovarian Hyperstimulation

Study the long-term carcinologic safety of Controlled Ovarian Hyperstimulation without Letrozole or Tamoxifen co-treatment in terms of survival without relapse

Survival without relapse defined by the time frame between the date of surgery and the date of the first recurrence

After chemotherapy ad until disease progression or death regardless of the cause, up to 10 years after chemotherapy

Inclusion Criteria: Patients included in the study CT 01614704 Informed and written consent Affiliated to the National Social Security System Exclusion Criteria: Impossibility to submit at the study procedures due to geographic, social or mental reasons Patient deprived of their liberty or under guardianship or tutorship.